Real-Time fMRI to Enhance Interventions That Change Delay Discounting

NCT ID: NCT04828577

Last Updated: 2025-01-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-01-13

Study Completion Date

2025-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators will use real-time fMRI neurofeedback to enhance participants' ability to control their temporal window, and hence their ability to modulate delay discounting and alcohol valuation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Based on 8 years of experience recruiting alcohol users into studies of comparable length and complexity, the investigators anticipate that 92% of consented participants will be eligible (i.e., randomized) and 97% of those individuals will complete Aim 2b. Thus, to achieve a final sample size of 100, the investigators anticipate consenting 111 participants. This study will include 50 real time fMRI (experimental group) participants and 50 "idealized" neurofeedback (control) participants. Participants will be randomly assigned to experimental or control groups, stratified by AUDIT scores, SES, age, and sex. All study procedures will take place during a single study visit. Before the imaging session, a research assistant will aid the participant to select salient images related to individualized future goals as well as alcohol images which elicit self-reported craving. All participants will complete two fMRI runs within a single session. In run 1 of the scan (offline classifier training), participants will perform an image viewing task displaying alternating blocks of these goal- and alcohol-related images. Between the image viewing blocks we will assess reinforcer pathology with brief in-scanner measures of delay discounting and alcohol valuation (BAAD). In total, there will be six blocks each of the goal-oriented images, alcohol-related images, delay discounting, and BAAD (24 blocks total). Since this is a proof-of-concept experiment, the interspersed delay discounting and BAAD blocks will enable monitoring and validating changes in the participant's temporal window and alcohol valuation after the image viewing blocks. Only the fMRI measures of goal- and alcohol-related image viewing will be used to build a support vector classifier (SVC) of decreased vs. increased delay discounting. If participants are allocated to the real time fMRI group, in run 2 the SVC model from run 1 will be used to provide participants with real-time neurofeedback while they attempt to modulate their temporal window. The participants will see a dial with a needle on the screen along with instructions to think of either future goals or alcohol cues. The dial will be directly controlled by ongoing output from the SVC, updating the needle position as participants imagine immediate (alcohol-related) or delayed (goal-related) cues. Control participants ("idealized" neurofeedback group) will undergo the same procedures, but in run 2 neurofeedback, will be presented with an "idealized" dial (perfect needle movements in both alcohol and goal directions) and will be specifically instructed that they are not controlling the interface. The investigators have used this type of sham needle movement as a control condition in previous experiments. Based on this, it is expected that experimental group will have increased whole brain signal to noise for alcohol vs. goal fMRI analyses and increased recruitment of frontal-parietal networks from enhanced visual attention to the task.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alcohol Use Disorder (AUD)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Real Time Neurofeedback

Real time neurofeedback will be based on a classifier of increasing or decreasing delay discounting fMRI patterns. Participants will try to modulate their discounting rate based on neurofeedback via a visual dial, during an fMRI scan. Participants will be told they will be controlling the visual dial.

Group Type EXPERIMENTAL

Real Time Neurofeedback

Intervention Type BEHAVIORAL

Participants receive feedback from own brain activity.

"Idealized"/Sham Neurofeedback

Rather than using the output of a classifier, the visual dial will display perfect "modulation" of increasing and decreasing delay discounting and participants will told that they will not be controlling the visual dial.

Group Type SHAM_COMPARATOR

"Idealized"/Sham Neurofeedback

Intervention Type BEHAVIORAL

Participants receive idealized feedback not related to their own brain activity.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Real Time Neurofeedback

Participants receive feedback from own brain activity.

Intervention Type BEHAVIORAL

"Idealized"/Sham Neurofeedback

Participants receive idealized feedback not related to their own brain activity.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* demonstrate high-risk or harmful drinking (AUDIT\>15)
* be 21 years of age or older
* have a desire to quit or cut down on their drinking, but do not have proximate plans to enroll in treatment for AUD during the study period

Exclusion Criteria

* meeting moderate to severe DSM-5 criteria for substance-use disorders other than alcohol or nicotine
* having a current diagnosis of any psychotic disorder
* having a history of seizure disorders or traumatic brain injury
* having any contraindication for participation in the MRI sessions
* reporting current pregnancy or lactation
Minimum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Fralin Biomedical Research Institute

UNKNOWN

Sponsor Role collaborator

Virginia Polytechnic Institute and State University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Stephen M LaConte, PhD

Role: PRINCIPAL_INVESTIGATOR

Fralin Biomedical Research Institute (FBRI) at VTC

Warren K Bickel, PhD

Role: PRINCIPAL_INVESTIGATOR

Fralin Biomedical Research Institute (FBRI) at VTC

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Fralin Biomedical Research Institute at VTC

Roanoke, Virginia, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RP2B/21-305

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Anxiety During Abstinence in AUD
NCT06793488 RECRUITING EARLY_PHASE1
Neural Mechanisms of Disulfiram Effects
NCT02735577 COMPLETED PHASE4